Up next

Supplier News: Cytiva, Evonik, Tjoapack & More 

The latest from CDMOs, CMOs, and suppliers featuring AtomVie, Cytiva/Fida Biosystems, Tjoapack, Bora Pharmaceuticals, Quotient Sciences/Intrepid Labs, CABB Chemicals, Quvara Medical, Pace, Evonik, Aptar, Sever Pharma, AmbioPharm and Benunvia/Cannovian.  

Chemicals/Chemical API Manufacturing 
* AtomVie Investing $138 M in New Radiopharma Mfg Facility 
* CABB Chemicals Agrees To Sale of Jayhawk Fine Chemicals 
Biologics Manufacturing 
* Cytiva, Fida Biosystems Partner for Analytics in Protein Research 
Formulation Development/Drug Product Manufacturing 
* Bora Pharmaceuticals, Corealis Pharma in Oral Solid Dose Pact 
* Quotient Sciences, Intrepid Labs in Pact for AI-Enabled Formulation Development 
Packaging 
* Tjoapack To Expand With New Packaging Facility 
* Quvara Medical Launches as a New Company 
* Aptar Acquires Sommaplast 
General 
* Benuvia, Cannovian Form Strategic Alliance for Controlled Substances 
Appointments 
* Pace Appoints New CEO
* Evonik Names New Head of the Americas 
* Sever Pharma Appoints New VP of Operations 
* AmbioPharm Appoints New General Manager 

Chemicals/Chemical API Manufacturing 

AtomVie Investing $138 M in New Radiopharma Mfg Facility 
AtomVie, a CDMO of radiopharmaceuticals, has announced plans to invest over $138 million into a new facility in Hamilton, Ontario, for producing radiopharmaceutical drug products, which would increase its capacity by at least 10-fold to manufacture radiopharmaceuticals for targeted cancer therapies. 

The investment is expected to create 70 new jobs. Subject to reaching a definitive agreement, it will be supported with a grant of up to $5 million through the Invest Ontario Fund. 

Source: Invest Ontario 

CABB Chemicals Agrees To Sale of Jayhawk Fine Chemicals 
The CABB Group, a chemical manufacturer, has signed a definitive agreement with Anupam Rasayan India, a specialty chemical manufacturer, to sell a 100% equity stake in its US-based production site in Galena, Kansas, Jayhawk Fine Chemicals Corporation, a manufacturer of advanced intermediates, active ingredients, and high-performance materials, for $150 million. 

Source: CABB Chemicals 

Biologics Manufacturing 

Cytiva, Fida Biosystems Partner for Analytics in Protein Research 
Cytiva and Fida Biosystems, a Danish company specializing in molecular analysis, have partnered to expand analytical capabilities for protein research. 

The collaboration combines Cytiva’s Biacore surface plasmon resonance (SPR) systems with Fidabio’s in-solution flow-induced dispersion analysis (FIDA) technology, providing both a complementary and an orthogonal approach that gives scientists a more complete picture of molecular interactions by linking structural details—such as protein size and stability—with precise binding and interaction data.  

Source: Cytiva 

Formulation Development/Drug Product Manufacturing 

Bora Pharmaceuticals, Corealis Pharma in Oral Solid Dose Pact 
Bora Pharmaceuticals, a Taipei City, Taiwan-based pharmaceutical company and CDMO of drug products, and Corealis Pharma, a Laval, Quebec, Canada-based contract provider of formulation development and clinical manufacturing of oral solid dosage forms, have entered into a strategic alliance to provide end-to-end services for oral solid dose development and manufacturing. In addition, the companies will offer unified project management and aligned quality.  

Source: Bora Pharmaceuticals 

Quotient Sciences, Intrepid Labs in Pact for AI-Enabled Formulation Development 
Quotient Sciences, a Nottingham, UK-based CDMO, and Intrepid Labs, a company applying artificial intelligence (AI) in pharmaceutical formulation science, have announced a new multi-year partnership to advance the use of AI in early drug development. 

Under the new agreement, Quotient Sciences will have access to Intrepid’s machine learning model, Andromeda, an AI platform to develop and optimize clinical performance of drug products. Andromeda provides exploration of formulation options to help reduce experimental burden, minimize drug-substance demands, and enhance data-driven decision making.  

The partnership builds on an existing collaboration where Intrepid’s AI model was incorporated into Quotient’s translational pharmaceutics platform to help accelerate the identification of optimal formulation compositions and reduce the time to transition new drug products into clinical development.  

Source: Quotient Sciences 

Packaging 

Tjoapack To Expand With New Packaging Facility 
Tjoapack, a contract packaging organization, has announced an investment to expand its operational footprint in the US with a new 170,000-square-foot facility adjacent to its existing site in Clinton, Tennessee. The expansion will feature a GMP suite, including packaging, labeling, cold-chain, and ambient storage capabilities. 

Scheduled for completion in early 2027, the new addition will support new high-speed packaging lines across a range of dosage forms, including oral solid dose (bottles and blisters) and injectable products (vials and auto-injectors), as well as various secondary packaging configurations. 

The Tjoapack US expansion builds on a series of enhancements to Tjoapack’s injectable packaging infrastructure over the past two years, including: 

  • An automated vial packaging line that features high-speed labeling, cartoning, and serialization capabilities, with an annual output of 15–20 million vials.;
  • A semi-automated auto-injector packaging line that enables advanced labeling, cartoning, and serialization functionality; and
  • A cold-storage expansion with a 2.5x increase in capacity went online in October 2024, adding 160 pallet spaces for products requiring 2–8°C storage conditions. 

Source: Tjoapack 

Quvara Medical Launches as New Company 
Buckland Group, an investment firm, has completed its acquisition of Becton Dickinson’s high-volume medical device production facility in Swindon, UK, and with the closing of the acquisiiton, has launched a new contract device manufacurer, Quvara Medical.  

Source: Buckland Group 

Aptar Acquires Sommaplast 
Aptar, a contract provider of drug-delivery and active material science products and services, has acquired Sommaplast, a provider of oral dosing pharma packaging solutions. 

Sommaplast was founded over 20 years ago and operates from a facility in Sao Paulo, Brazil with a team of over 400 employees. Aptar currently has manufacturing facilities in Cajamar, Jundiaí, Maringá, and Camaçari, Brazil, and this transaction expands the company’s presence in Latin America and brings together shared manufacturing strengths. 

Source: Aptar 

General 

Benuvia, Cannovian Form Strategic Alliance for Controlled Substances 
Benuvia Operations, a CDMO of active pharmaceutical ingredients and drug products, has entered a partnership with Cannovation Clinical Research Partners (CCRP), a global consultancy focused on cannabinoid and psychedelic therapeutic programs. Together, the organizations will create an integrated manufacturing and contract research organization platform dedicated to Schedule I–V substances. 

The collaboration combines Benuvia’s end-to-end capabilities in controlled-substance manufacturing, analytical testing, and CMC development with CCRP’s expertise in preclinical and clinical research, regulatory strategy, and global trial execution. Through this partnership, companies gain a single pathway from early-stage development through commercialization for cannabinoid, psychedelic, and central nervous system therapeutics. 

 Source: Benuvia Operations 

Appointments 

Pace Appoints New CEO 
Pace, a science and technology company, has announced the appointment of Ken Beyer, formelry CEO of Transportation Insight and Nolan Transportation Group, domestic transportation-management providers, as its new CEO.  

Prior to his CEO role at Transportation Insight and Nolan Transportation, Beyer previously served as President of Ingram Micro Commerce & Lifecycle Services, a $4-billion global logistics business spanning 39 countries and 15,000 employees. He joined Ingram Micro after its acquisition of CloudBlue Technologies, a company he co-founded and scaled into a global provider in reverse logistics and IT asset disposition. Beyer began his career as a management consultant with Ernst & Young.  

Source: Pace 

Evonik Names New Head of the Americas 
Evonik, a specialty chemicals, fine chemicals, and nutritional ingredients producer, has appointed long-time Evonik executive Elias Lacerda, currently Head of Evonik’s Coating Additives Business Line, as President of the Americas region, effective February 1, 2026. Lacerda will succeed Guido Skudlarek, who recently became Global Head of Evonik’s US-based Health Care Business Line. 

Lacerda has nearly three decades of experience with Evonik and its predecessor companies. He spent half of that time in Central and South America (CSA) managing businesses in the coatings sector and holding global leadership positions in Evonik’s silica and animal nutrition business lines. Most recently, he served as Head of the Coating Additives Business Line at the company’s headquarters in Essen, Germany. From 2018 to 2022, he led the CSA region as President. The CSA and North America regions were recently merged. 

Source: Evonik 

Sever Pharma Appoints New VP of Operations 
Sever Pharma Solutions, a CDMO specializing in controlled-release drug-delivery systems for highly potent drugs, has appointed Linda Rebert, currently the company’s Director of Engineering and Operational Excellence, as its new Vice President of Operations. 

Rebert has been a member of the Sever Pharma Solutions team since 2020, initially leading the quality control department. During the past year, she has been responsible for the engineering and operational excellence function. She has extensive experience from the bioscience and pharmaceutical industries, having previously held management positions at Chr. Hansen and the PolyPeptide Group.  

Source: Sever Pharma Solutions 

AmbioPharm Appoints New General Manager 
AmbioPharm, a CDMO focused on peptides, has appointed Wen Du, currently Senior Director, Head of Operations at Lonza, as General Manager of AmbioPharm Shanghai.  

Prior to joining AmbioPharm, he held senior leadership roles at Lonza, including Senior Director, Head of Operations for mammalian monoclonal antibody production and cell banking at Lonza’s  Visp, Switzerland, site, and Manufacturing and Supply Chain Director at Lonza’s Guangzhou, China’s biologics facility. He also served as Supply Chain Director for Takeda’s Tiajin site and Head of its China logistics center. 

Source: AmbioPharm